The role of the T3 molecular complex on human T lymphocyte-mediated cytotoxicity. 1985

C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson

The above overview of the experimental data clearly indicates that the T3 molecular complex is intimately involved in T cell activation. The precise role of the T3 complex in the activation process, however, is not clearly understood. The surface association of the T3 complex with the antigen receptor, along with the ability of antibodies to these molecules to render T cells receptive to IL2, reveal a possible mechanism by which specific antigen initiates T cell activation and growth. However, it would be difficult to reconcile this specific effect of anti-T3 antibodies with their effect on CTL function. Since the T3 complex is not a specific marker of any particular effector T cell population, but it is found on all T lymphocytes, we favor the hypothesis that the complex is involved in a more fundamental step of T cell activation, and we believe that triggering of the 'lethal hit', expression of IL2 receptors, and secretion of IL2 are mere manifestations of this basic process. The natural ligand of the antigen receptor is obviously the specific antigen. However, the natural ligand of the T3 complex is unknown. Possibly, its natural ligand is the antigen receptor itself after it has interacted with antigen. A simple scenario, then of the early events of T cell activation would include antigen recognition and binding, followed by an interaction between the antigen receptor and the T3 complex which then activates or allows expression of specific pathways depending on the particular effector population involved. Thus, the inhibition of CTL function by anti-T3 antibodies could be explained by interference with the antigen receptor-T3 complex interaction following target cell recognition. This interaction may be the event that signals the initiation of the 'lethal hit' process.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000954 Antigens, Surface Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated. Cell Surface Antigens,Surface Antigens,Surface Markers, Immunological,Cell Surface Antigen,Immunologic Surface Markers,Markers, Immunological Surface,Surface Antigen,Surface Markers, Immunologic,Antigen, Cell Surface,Antigen, Surface,Antigens, Cell Surface,Immunological Surface Markers,Markers, Immunologic Surface,Surface Antigen, Cell,Surface Antigens, Cell
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
December 1982, Clinical and experimental immunology,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
March 1987, Human immunology,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
January 1986, Symposium on Fundamental Cancer Research,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
August 2005, Cellular & molecular immunology,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
January 1981, Progress in clinical and biological research,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
April 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
August 2000, Microscopy research and technique,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
January 1977, International archives of allergy and applied immunology,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
January 2021, Frontiers in immunology,
C D Tsoukas, and M Valentine, and M Lotz, and J H Vaughan, and D A Carson
January 1975, Archiv fur Geschwulstforschung,
Copied contents to your clipboard!